Discover 2,356 paid clinical trials in Oceanside, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 2,356
A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
for
Metastatic Castration-resistant Prostate Cancer
Location: La Jolla CA, San Antonio TX, Milwaukee WI,
Sponsor: Daiichi Sankyo
Sex: Male
Age: 18+
Code: NCT07244341
Phase 1, Recruiting
Retifanlimab and Ruxolitinib In Solid Malignancies
for
Non Small Cell Lung Carcinoma, Renal Cell Carcinoma
Location: La Jolla CA
Sponsor: University of California, San Diego
Sex: All
Age: 0+
Code: NCT07219576
Phase 1, Phase 2, Recruiting
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
for
Head and Neck Squamous Cell Carcinoma HNSCC,
Location: San Diego CA, Denver CO, San Antonio TX, Austin TX,
Sponsor: Sutro Biopharma, Inc.
Sex: All
Age: 18+
Code: NCT07227168
Phase 1, Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
for
Cervical Cancer
Location: La Jolla CA, Irvine CA, Orange CA, Las Vegas NV,
Sponsor: Merck Sharp & Dohme LLC
Sex: Female
Age: 18+
Code: NCT07216703
Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
for
Pancreatic Cancer, PDAC,
Location: La Jolla CA, Los Angeles CA, Las Vegas NV, Phoenix AZ,
Sponsor: Revolution Medicines, Inc.
Sex: All
Age: 18+
Code: NCT07252232
Phase 3, Recruiting
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Location: San Diego CA, Los Angeles CA, San Francisco CA,
Sponsor: Pierre Fabre Medicament
Sex: All
Age: 18+
Code: NCT04913285
Phase 1, Recruiting
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
for
Locally Advanced Adrenal Cortical Carcinoma,
Location: La Jolla CA, Madera CA, Phoenix AZ, Aurora CO,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 12+
Code: NCT06900595
Phase 2, Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
for
Breast Neoplasms
Location: La Jolla CA, Los Alamitos CA, Los Angeles CA,
Sponsor: BioNTech SE
Sex: All
Age: 18+
Code: NCT07173751
Phase 3, Recruiting
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
for
Prostate Cancer (Adenocarcinoma),
Location: La Jolla CA, Duarte CA, Seattle WA, Minneapolis MN,
Sponsor: Prostate Cancer Clinical Trials Consortium
Sex: Male
Age: 18+
Code: NCT06844383
Phase 2, Recruiting
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
for
Anatomic Stage I Breast Cancer AJCC v8,
Location: La Jolla CA, San Diego CA, Irvine CA, Orange CA,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 18+
Code: NCT06876714
Phase 3, Recruiting
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
for
Castration-Sensitive Prostate Carcinoma,
Location: La Jolla CA, San Diego CA, Rancho Mirage CA, Fresno CA,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: Male
Age: 18+
Code: NCT06931340
Phase 3, Recruiting
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
for
Buccal Mucosa Squamous Cell Carcinoma,
Location: La Jolla CA, San Diego CA, Phoenix AZ, Gilbert AZ,
Sponsor: NRG Oncology
Sex: All
Age: 18+
Code: NCT04333537
Phase 2, Phase 3, Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: La Jolla CA, Irvine CA, Los Alamitos CA, Los Angeles CA,
Sponsor: BeOne Medicines
Sex: All
Age: 18+
Code: NCT06973187
Phase 3, Recruiting
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
for
Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer,
Location: La Jolla CA, Los Angeles CA, Houston TX, Minneapolis MN,
Sponsor: Fate Therapeutics
Sex: All
Age: 18+
Code: NCT07216105
Phase 1, Recruiting
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Location: La Jolla CA, Irvine CA, Orange CA, Santa Barbara CA,
Sponsor: NRG Oncology
Sex: All
Age: 18+
Code: NCT06958328
Phase 3, Recruiting
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
for
Core Binding Factor Acute Myeloid Leukemia
Location: La Jolla CA, Salt Lake City UT, Albuquerque NM,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18 - 59
Code: NCT06917911
Phase 2, Recruiting
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
for
Pancreatic Neoplasm
Location: La Jolla CA, Loma Linda CA, Los Angeles CA, Burbank CA,
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: All
Age: 50 - 70+
Code: NCT04239573
Recruiting
Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
for
Basal Cell Carcinoma
Location: La Jolla CA, Irvine CA, San Francisco CA
Sponsor: University of California, San Diego
Sex: All
Age: 18+
Code: NCT06624475
Phase 2, Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors